E. Punnoose, J. D. Leverson, E. R. Boghaert, L. Belmont, W. J. Fairbrother et al., Sampath Development of methodology Acquisition of data (provided animals, acquired and managed patients, provided facilities Maiga Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis Sampath Writing, review, and/or revision of the manuscript The prognostic significance of cytogenetics and molecular profiling in multiple myeloma, J. Souers, D. Sampath Study Cancer Genet, vol.204, pp.3-12, 2011.

G. Bianchi, P. Richardson, and K. Anderson, Promising therapies in multiple myeloma, Blood, vol.126, issue.3, pp.2015-2018, 2015.
DOI : 10.1182/blood-2015-03-575365

J. Chipuk, T. Moldoveanu, F. Llambi, M. Parsons, and D. Green, The BCL-2 Family Reunion, Molecular Cell, vol.37, issue.3, pp.299-310, 2010.
DOI : 10.1016/j.molcel.2010.01.025

J. Adams and C. S. , Bcl-2-regulated apoptosis: mechanism and therapeutic potential, Current Opinion in Immunology, vol.19, issue.5, pp.488-96, 2007.
DOI : 10.1016/j.coi.2007.05.004

P. Czabotar, G. Lessene, A. Strasser, and J. Adams, Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy, Nature Reviews Molecular Cell Biology, vol.5, issue.1, pp.49-63, 2014.
DOI : 10.1038/sj.cdd.4402178

B. Zhang, I. Gojo, and R. Fenton, Myeloid cell factor-1 is a critical survival factor for multiple myeloma, Blood, vol.99, issue.6, pp.1885-93, 2002.
DOI : 10.1182/blood.V99.6.1885

S. Derenne, B. Monia, N. Dean, J. Taylor, M. Rapp et al., Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells, Blood, vol.100, issue.1, pp.194-203, 2002.
DOI : 10.1182/blood.V100.1.194

P. Gomez-bougie, R. Bataille, and M. Amiot, The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells, European Journal of Immunology, vol.379, issue.11, pp.3156-64, 2004.
DOI : 10.1002/eji.200424981

S. Wuill-eme-toumi, N. Robillard, and P. Gomez, Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival, Leukemia, vol.96, issue.7, pp.1248-52, 2005.
DOI : 10.1093/jnci/djh122

T. Oltersdorf, S. Elmore, A. Shoemaker, R. Armstrong, and D. Augeri, An inhibitor of Bcl-2 family proteins induces regression of solid tumours, Nature, vol.20, issue.7042, pp.677-81, 2005.
DOI : 10.1016/0014-5793(95)00062-E

D. Chauhan, M. Velankar, M. Brahmandam, T. Hideshima, K. Podar et al., A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma, Oncogene, vol.275, issue.16, pp.2374-80, 2007.
DOI : 10.1038/sj.onc.1210028

M. Kline, S. Rajkumar, M. Timm, T. Kimlinger, J. Haug et al., ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells, Leukemia, vol.3, issue.7, pp.1549-60, 2007.
DOI : 10.1038/sj.onc.1208949

S. Trudel, A. Stewart, Z. Li, Y. Shu, S. Liang et al., The Bcl-2 Family Protein Inhibitor, ABT-737, Has Substantial Antimyeloma Activity and Shows Synergistic Effect with Dexamethasone and Melphalan, Clinical Cancer Research, vol.13, issue.2, pp.621-630, 2007.
DOI : 10.1158/1078-0432.CCR-06-1526

C. Tse, A. Shoemaker, J. Adickes, M. Anderson, J. Chen et al., ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor, Cancer Research, vol.68, issue.9, pp.3421-3429, 2008.
DOI : 10.1158/0008-5472.CAN-07-5836

L. Bodet, P. Gomez-bougie, C. Touzeau, C. Dousset, G. Descamps et al., ABT-737 is highly effective against molecular subgroups of multiple myeloma, Blood, vol.118, issue.14, pp.3901-3911, 2011.
DOI : 10.1182/blood-2010-11-317438

M. Van-delft, A. Wei, K. Mason, C. Vandenberg, L. Chen et al., The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized, Cancer Cell, vol.10, issue.5, pp.389-99, 2006.
DOI : 10.1016/j.ccr.2006.08.027

S. Tahir, X. Yang, M. Anderson, S. Morgan-lappe, A. Sarthy et al., Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737, Cancer Research, vol.67, issue.3, pp.1176-83, 2007.
DOI : 10.1158/0008-5472.CAN-06-2203

A. Morales, M. Kurtoglu, S. Matulis, J. Liu, D. Siefker et al., Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells, Blood, vol.118, issue.5, pp.1329-1368, 2011.
DOI : 10.1182/blood-2011-01-327197

J. Leverson, H. Zhang, J. Chen, S. Tahir, D. Phillips et al., Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax), Cell Death and Disease, vol.15, issue.1, p.1590, 2015.
DOI : 10.1172/JCI39964

H. Zhang, P. Nimmer, S. Tahir, J. Chen, R. Fryer et al., Bcl-2 family proteins are essential for platelet survival, Cell Death and Differentiation, vol.53, pp.943-51, 2007.
DOI : 10.1097/01.fjc.0000171755.28317.85

K. Mason, M. Carpinelli, J. Fletcher, J. Collinge, A. Hilton et al., Programmed Anuclear Cell Death Delimits Platelet Life Span, Cell, vol.128, issue.6, pp.1173-86, 2007.
DOI : 10.1016/j.cell.2007.01.037

A. Souers, J. Leverson, E. Boghaert, S. Ackler, N. Catron et al., ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, Nature Medicine, vol.559, issue.2, pp.202-210, 2013.
DOI : 10.1038/leu.2009.151

C. Touzeau, C. Dousset, L. Gouill, S. Sampath, D. Leverson et al., The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma, Leukemia, vol.21, issue.1, pp.210-212, 2014.
DOI : 10.1038/leu.2013.216

Z. Tao, L. Hasvold, L. Wang, X. Wang, A. Petros et al., Activity, ACS Medicinal Chemistry Letters, vol.5, issue.10, pp.1088-93, 2014.
DOI : 10.1021/ml5001867
URL : https://hal.archives-ouvertes.fr/in2p3-00012185

J. Leverson, D. Phillips, M. Mitten, E. Boghaert, D. Diaz et al., Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy, Science Translational Medicine, vol.7, issue.279, pp.279-319, 2015.
DOI : 10.1126/scitranslmed.aaa4642

M. Certo, D. G. Moore, V. Nishino, M. Wei, G. Korsmeyer et al., Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members, Cancer Cell, vol.9, issue.5, pp.351-65, 2006.
DOI : 10.1016/j.ccr.2006.03.027

R. Pan, L. Hogdal, J. Benito, D. Bucci, L. Han et al., Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia, Cancer Discovery, vol.4, issue.3, pp.362-75, 2014.
DOI : 10.1158/2159-8290.CD-13-0609

J. Qin, J. Ziffra, L. Stennett, B. Bodner, B. Bonish et al., Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells, Cancer Research, vol.65, issue.14, pp.6282-93, 2005.
DOI : 10.1158/0008-5472.CAN-05-0676

P. Gomez-bougie, S. Wuill-eme-toumi, E. Trichet, V. Robillard, N. Philippe et al., Noxa Up-regulation and Mcl-1 Cleavage Are Associated to Apoptosis Induction by Bortezomib in Multiple Myeloma, Cancer Research, vol.67, issue.11, pp.5418-5442, 2007.
DOI : 10.1158/0008-5472.CAN-06-4322

P. Gomez-bougie, E. Juin, P. Dousset, C. Pellat-deceunynck, C. Amiot et al., Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1/USP9X interaction, Biochemical and Biophysical Research Communications, vol.413, issue.3, pp.460-464, 2011.
DOI : 10.1016/j.bbrc.2011.08.118

S. Ackler, M. Mitten, K. Foster, A. Oleksijew, M. Refici et al., The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo, Cancer Chemotherapy and Pharmacology, vol.88, issue.Suppl 1, pp.869-80, 2010.
DOI : 10.1007/s00280-009-1232-1

R. Thijssen, E. Slinger, K. Weller, C. Geest, T. Beaumont et al., Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors, Haematologica, vol.100, pp.302-308, 2015.
DOI : 10.3324/haematol.2015.124560

D. Chiron, C. Dousset, C. Brosseau, C. Touzeau, S. Ma?-ga et al., Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma, Oncotarget, vol.6, issue.11, pp.8750-8759, 2015.
DOI : 10.18632/oncotarget.3275

J. Bogenberger, S. Kornblau, W. Pierceall, R. Lena, D. Chow et al., BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies, Leukemia, vol.70, issue.8, pp.1657-65, 2014.
DOI : 10.1158/1535-7163.MCT-07-0010

D. Gaizo-moore, V. Letai, and A. , BH3 profiling ??? Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions, Cancer Letters, vol.332, issue.2, pp.202-207, 2013.
DOI : 10.1016/j.canlet.2011.12.021

C. Touzeau, J. Ryan, J. Guerriero, P. Moreau, T. Chonghaile et al., BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics, Leukemia, vol.120, issue.3, pp.761-64, 2016.
DOI : 10.1016/j.ymeth.2013.04.006
URL : https://hal.archives-ouvertes.fr/inserm-01411102

S. Kumar, R. Vij, J. Kaufman, J. Mikhael, T. Facon et al., Phase I Interim Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM), Clinical Lymphoma Myeloma and Leukemia, vol.15, issue.8576, p.2015
DOI : 10.1016/j.clml.2015.07.630

C. Touzeau, A. Chanan-khan, A. Roberts, A. Agarwal, T. Facon et al., Phase 1b Interim Results: Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib (BTZ) and Dexamethasone (Dex) in Relapsed/Refractory (R/R) Multiple Myeloma (MM), Clinical Lymphoma Myeloma and Leukemia, vol.15, issue.8580, p.2015
DOI : 10.1016/j.clml.2015.07.568